Your browser doesn't support javascript.
loading
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.
Atyeo, Caroline; Fischinger, Stephanie; Zohar, Tomer; Slein, Matthew D; Burke, John; Loos, Carolin; McCulloch, Denise J; Newman, Kira L; Wolf, Caitlin; Yu, Jingyou; Shuey, Kiel; Feldman, Jared; Hauser, Blake Marie; Caradonna, Tim; Schmidt, Aaron G; Suscovich, Todd J; Linde, Caitlyn; Cai, Yongfei; Barouch, Dan; Ryan, Edward T; Charles, Richelle C; Lauffenburger, Douglas; Chu, Helen; Alter, Galit.
Afiliação
  • Atyeo C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; PhD Program in Virology, Division of Medical Sciences, Harvard University, Boston, MA, USA.
  • Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; PhD Program in Immunology and Virology, University of Duisburg-Essen, Essen, Germany.
  • Zohar T; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Slein MD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Burke J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Loos C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • McCulloch DJ; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Newman KL; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Wolf C; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Shuey K; Department of Medicine, University of Washington, Seattle, WA, USA.
  • Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Hauser BM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Caradonna T; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Schmidt AG; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Suscovich TJ; SeromYx Systems, Cambridge, MA, USA.
  • Linde C; SeromYx Systems, Cambridge, MA, USA.
  • Cai Y; Division of Molecular Medicine, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Barouch D; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Ryan ET; Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA.
  • Charles RC; Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA.
  • Lauffenburger D; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Chu H; Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: helenchu@uw.edu.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Electronic address: galter@partners.org.
Immunity ; 53(3): 524-532.e4, 2020 09 15.
Article em En | MEDLINE | ID: mdl-32783920
As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Proteínas do Nucleocapsídeo / Glicoproteína da Espícula de Coronavírus / Anticorpos Antivirais Tipo de estudo: Qualitative_research Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Proteínas do Nucleocapsídeo / Glicoproteína da Espícula de Coronavírus / Anticorpos Antivirais Tipo de estudo: Qualitative_research Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article